Journals / Glokom Katarakt / 2009 / Cilt: 4 - Sayı: 1

Revaluation of patient diagnosis and treatment who were started on antigulaucoma

Antiglokomatöz ilaç başlanmış hastaların tanı ve tedavilerinin tekrar değerlendirilmesi

Pages
57–60
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Discussion: Careful evaluation of the patients and doing the required tests before starting glaucoma treatment will increase the accuracy of the therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The patients whose antiglaucomatous medication was stopped, because no glaucoma damage was detected, were followed closely and long term follow-up results were evaluated.
📊
Key Findings & Data:Materials and Methods: The glaucoma medication of 91 patients, who started antiglaucomatous medication but who had no detectable glaucoma damage in examinations and tests done in our clinic, were stopped.
💡
Conclusion & Impact:Discussion: Careful evaluation of the patients and doing the required tests before starting glaucoma treatment will increase the accuracy of the therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: The patients whose antiglaucomatous medication was stopped, because no glaucoma damage was detected, were followed closely and long term follow-up results were evaluated. Materials and Methods: The glaucoma medication of 91 patients, who started antiglaucomatous medication but who had no detectable glaucoma damage in examinations and tests done in our clinic, were stopped. The IOP, standard and short wave perimetry results, central corneal thickness, optic disc analyses with confocal scanning laser ophthalmoscopy or patients were evaluated. Results: Seventy eight (85.71%) of the 91 patients, whose medications were stopped and followed, were under glaucoma therapy on initial visit, 13 had glaucoma treatment initiated in our clinic. The patients were followed for 32.95±16.32 (6-96) months. In the follow ups 7 (7.69%) out of 91 patients were found to have glaucomotous changed and therapy was restarted. Of the remaining 84 patients, 35 were considered as ocular hypertension and 49 as healthy eyes. Discussion: Careful evaluation of the patients and doing the required tests before starting glaucoma treatment will increase the accuracy of the therapy.

Özet

Amaç: Antiglokomatöz ilaç tedavisi glokom hasarı saptanmadığı için kesilerek yakından izlenen hastaların uzun dönem takip sonuçları değerlendirildi. Gereç ve Yöntem: Primer açık açılı glokom (PAAG) tanısı ile ilaç tedavisi başlanmış ancak kliniğimizde yapılan muayene ve tetkiklerde glokomatöz hasar izlenmeyen 91 hastanın kulandığı antiglokomatöz ilaçlar kesildi. Hastaların, göz içi basıncı (GİB) , standart ve kısa dalga boyu otomatik perimetre sonuçları, santral kornea kalınlıkları, konfokal tarayıcı lazer oftalmoskop ile optik disk analizleri değerlendirildi. Bulgular: İlaçları kesilerek izleme alınan 91 hastanın 78’i (%85.71) kliniğimize başvurduğunda antiglokomatöz ilaç kullanıyordu. 13’üne kliniğimizde ilaç başlanmıştı. Hastalar ilaçsız olarak 32.95±16.32 (6-96) ay izlendi. İzlemlerde 91 hastanın 7’sinde (%7.69) glokomatöz değişiklikler tespit edilip tekrar ilaca başlandı. Geri kalan 84 hastanın 35’inde oküler hipertansiyon, 49 hastanın gözleri sağlıklı olarak değerlendirildi. Sonuç: Glokom tedavisine başlanmadan önce hastaların dikkatlice değerlendirilmesi ve gerekli tetkiklerin yapılması tedavi yaklaşımının doğruluğunu arttıracaktır.

🔖

Cite This Article

KAYIKÇIOĞLU, Ö. R., KAYA, Y. Z. (2009). Revaluation of patient diagnosis and treatment who were started on antigulaucoma. Glokom Katarakt, Cilt: 4 - Sayı: 1, 57–60. https://ajindex.com/articles/226912

References (15)

  1. Heijl A, Leske MC, Bengtsson B, et al.: for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268-1279
  2. Quigley HA, Addicks EM, Green WR.: Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol. 1982;100: 135-146
  3. Whitacre MM, Stein RA, Hassanein K.: The effect of corneal thickness on applanation tonometry. Am J Ophthalmol. 1993;115: 592-596
  4. Zeyen TG, Caprioli J.: Progression of disease and vision field damage in early glaucoma. Arc Ophthalmol. 1993;111:62-65
  5. Landers JA, Goldberg I, Graham SL.: Detection of Early Visual Field Loss in Glaucoma Using Frequency-Doubling Perimetry and Short-Wavelength Automated Perimetry. Arch Ophthalmol. 2003; 121:1705-1710
  6. Johnson CA, Brandt JD, Khong AM, at al.: Short-wavelength automated perimetry in low-, medium-, and high-risk ocular hypertensive eyes. Initial baseline results. Arch Ophthalmol. 1995;113: 70-76
  7. Caprioli J.: Should we use short-wavelength automated perimetry to test glaucoma patients? Am J Ophthalmol. 2001;131:792-794
  8. Doughty MJ, Zaman ML.: Human corneal thickness and its impact on intraocular pressure measures. Surv Ophthalmol. 2000; 44:367-408
  9. Whitacre MM, Stein RA, Hassanein K.: The effect of corneal thickness on applanation tonometry. Am J Ophthalmol. 1993;115: 592-596
  10. Ehlers N, Bramsen T, Sperling S: Applanation tonometry and central thickness. Acta Ophthalmol. 1975;53:34-43
  11. Gordon MO, Beiser JA, Brandt JD, et al.: The ocular hypertension treatment study: Baseline factors that predict the onset of primary open angle glaucoma. Arch Ophthalmol. 2002;120:714-720
  12. Johnson CA, Adams AJ, Casson EJ, et.al.: Blue-on-yellow perimetry can predict the development of glaucomatous visual field loss. Arch Ophthalmol. 1993;111:645-650
  13. Johnson CA, Adams AJ, Casson EJ, et.al.: Progression of early glaucomatous visual field loss as detected by blue-on-yellow and standart white-on-white automated perimetry. Arch Ophthalmol. 1993;111:651-656
  14. Kass MA, Heuer DK, Higginbotham EJ, et al.: The ocular hypertension treatment study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120: 701-713
  15. Rylande